Who
David L. Lowrance
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Savara; CFO, Secretary, Treasurer, Acucela; Vice President and CFO, Cumberland Pharmaceuticals.
In numbers
- Trades disclosed
- 126
- Buys
- 3
- Sells
- 14
- Bought
- $35K
- Sold
- $5.4M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 26 Mar 2010
- Last trade
- 22 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 22 Jun 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code M | $119K75,000 at $1.59 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code F | $56K10,114 at $5.50 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code M | $294K87,650 at $3.35 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code F | $294K53,387 at $5.50 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Sold | $2.2M394,528 at $5.68 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —75,000 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —129,350 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,937 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —218,750 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —87,650 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code F | $119K21,682 at $5.50 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code M | $159K129,350 at $1.23 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —75,000 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —129,350 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,937 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —218,750 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —87,650 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code F | $159K28,928 at $5.50 | filing |
News
No headline names them, or the companies they trade most, lately.